Sanofi (SNY - Free Report) closed at $51.54 in the latest trading session, marking a +1.3% move from the prior day. This move outpaced the S&P 500's daily gain of 0.62%. Elsewhere, the Dow gained 0.5%, while the tech-heavy Nasdaq lost 5.66%.
Prior to today's trading, shares of the drugmaker had lost 6.76% over the past month. This has lagged the Medical sector's loss of 2.88% and the S&P 500's gain of 3.44% in that time.
Sanofi will be looking to display strength as it nears its next earnings release. The company is expected to report EPS of $0.87, down 5.43% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $11.41 billion, up 5.89% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $4.47 per share and revenue of $49.32 billion, which would represent changes of +2.76% and +9.2%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for Sanofi. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.37% lower within the past month. Sanofi is holding a Zacks Rank of #3 (Hold) right now.
In terms of valuation, Sanofi is currently trading at a Forward P/E ratio of 11.39. This represents a discount compared to its industry's average Forward P/E of 14.65.
Investors should also note that SNY has a PEG ratio of 1.66 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. SNY's industry had an average PEG ratio of 1.66 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 62, which puts it in the top 25% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
Where Will Stocks Go…
If Biden Wins? If Trump Wins?
The answers may surprise you.
Since 1950, even after negative midterm years, the market has never had a lower presidential election year. With voters energized and engaged, the market has been almost unrelentingly bullish no matter which party wins!
Now is the time to download Zacks' free Special Report with 5 stocks that offer extreme upside for both Democrats and Republicans…
1. Medical manufacturer has gained +11,000% in the last 15 years.
2. Rental company is absolutely crushing its sector.
3. Energy powerhouse plans to grow its already large dividend by 25%.
4. Aerospace and defense standout just landed a potentially $80 billion contract.
5. Giant Chipmaker is building huge plants in the U.S.
Hurry, Download Special Report FREE >>
Sanofi (SNY - Free Report) closed at $51.54 in the latest trading session, marking a +1.3% move from the prior day. This move outpaced the S&P 500's daily gain of 0.62%. Elsewhere, the Dow gained 0.5%, while the tech-heavy Nasdaq lost 5.66%.
Prior to today's trading, shares of the drugmaker had lost 6.76% over the past month. This has lagged the Medical sector's loss of 2.88% and the S&P 500's gain of 3.44% in that time.
Sanofi will be looking to display strength as it nears its next earnings release. The company is expected to report EPS of $0.87, down 5.43% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $11.41 billion, up 5.89% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $4.47 per share and revenue of $49.32 billion, which would represent changes of +2.76% and +9.2%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for Sanofi. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.37% lower within the past month. Sanofi is holding a Zacks Rank of #3 (Hold) right now.
In terms of valuation, Sanofi is currently trading at a Forward P/E ratio of 11.39. This represents a discount compared to its industry's average Forward P/E of 14.65.
Investors should also note that SNY has a PEG ratio of 1.66 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. SNY's industry had an average PEG ratio of 1.66 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 62, which puts it in the top 25% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
Where Will Stocks Go…
If Biden Wins? If Trump Wins?
The answers may surprise you.
Since 1950, even after negative midterm years, the market has never had a lower presidential election year. With voters energized and engaged, the market has been almost unrelentingly bullish no matter which party wins!
Now is the time to download Zacks' free Special Report with 5 stocks that offer extreme upside for both Democrats and Republicans…
1. Medical manufacturer has gained +11,000% in the last 15 years.
2. Rental company is absolutely crushing its sector.
3. Energy powerhouse plans to grow its already large dividend by 25%.
4. Aerospace and defense standout just landed a potentially $80 billion contract.
5. Giant Chipmaker is building huge plants in the U.S.
Hurry, Download Special Report FREE >>
Get the latest research report on SNY - FREE